HIV infection is a chronic retroviral infection that destroys CD4 T lymphocytes; untreated, it ends in AIDS (acquired immunodeficiency syndrome), defined by CD4 below 200/µL or an AIDS-defining illness, with opportunistic infections and tumours.
Key to diagnosis: a fourth-generation antigen/antibody test, confirmed by an HIV-1/HIV-2 differentiation assay and, if discordant or in suspected acute infection, HIV RNA. Then CD4 count, viral load and resistance genotype. Think of HIV when thrush, zoster, weight loss or Pneumocystis pneumonia appear in a young adult.
Key to treatment: antiretroviral therapy (ART) for everyone at any CD4 count, started rapidly, with an integrase inhibitor-based regimen; treat and prevent opportunistic infections, and time ART correctly in TB and cryptococcal meningitis. Epidemiology, transmission, testing strategy, PrEP, PEP and mother-to-child prevention: topic 3.
Etiology and pathogenesis
HIV-1 (groups M, N, O, P; group M causes the pandemic) and HIV-2 (mostly West Africa; slower course). HIV-2 is intrinsically resistant to NNRTIs and enfuvirtide, so regimens differ.
The virus enters CD4 cells through gp120 binding to CD4 and a co-receptor (CCR5 or CXCR4), copies its RNA to DNA by reverse transcriptase, integrates it into the host genome with integrase, and assembles new virions with protease. Integrated provirus in resting cells forms a latent reservoir that ART does not eradicate, so treatment is lifelong.
The gut-associated lymphoid tissue is depleted in the first weeks; chronic immune activation and inflammation then drive CD4 loss and many non-AIDS illnesses.
Natural history: acute infection with very high viraemia, fall to a viral set point, then CD4 loss of about 50-100/µL a year; AIDS appears at a median of about 10 years without treatment.